NCT01751451 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|OHSU Knight Cancer Institute|Rutgers Cancer Institute of New Jersey|NorthShore University HealthSystem|Duke University|Northwestern University Feinberg School of Medicine|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|University of North Carolina|Wayne State University|Perlmutter New York University Cancer Center|Weill Medical College of Cornell University|Ferring Pharmaceuticals|GU Research Network, LLC|University of California, Los Angeles | Prostate Cancer | December 18, 2012 | Phase 2 |
NCT02415621 | H. Lee Moffitt Cancer Center and Research Institute | Prostate Cancer | April 13, 2015 | Early Phase 1 |
NCT01913015 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer | July 2013 | Phase 1 |
NCT04947254 | M.D. Anderson Cancer Center | Prostate Carcinoma|Stage IIC Prostate Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8 | August 5, 2021 | Phase 2 |
NCT03098836 | Daniel George, MD|Janssen Scientific Affairs, LLC|Duke University | Prostate Cancer | July 10, 2017 | Phase 2 |
NCT01867710 | Janssen Pharmaceutica N.V., Belgium | Prostate Cancer | July 16, 2013 | Phase 2 |
NCT01717053 | Duke University|Janssen Pharmaceuticals | Prostate Cancer | January 17, 2014 | Phase 2 |
NCT04458311 | Institute of Cancer Research, United Kingdom|Sun Pharmaceutical Industries Limited | Metastatic Castration Resistant Prostate Cancer | December 1, 2020 | Phase 1|Phase 2 |
NCT02217566 | Janssen Research & Development, LLC | Prostatic Neoplasms | September 23, 2014 | Phase 2 |
NCT03431350 | Janssen Research & Development, LLC | Prostatic Neoplasms, Castration-Resistant | March 2, 2018 | Phase 1|Phase 2 |
NCT01591122 | Janssen Research & Development, LLC | Prostate Cancer | March 27, 2012 | Phase 3 |
NCT04493853 | AstraZeneca | Hormone-Sensitive Prostate Cancer | July 13, 2020 | Phase 3 |
NCT02543255 | University Health Network, Toronto | Prostate Cancer | September 2016 | Phase 2 |
NCT04736108 | West China Hospital | Prostate Cancer | May 2021 | Phase 2 |
NCT03043807 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Prostate Cancer | February 22, 2017 | Phase 2 |
NCT01254864 | M.D. Anderson Cancer Center|Bristol-Myers Squibb|Janssen Scientific Affairs, LLC|Pfizer | Prostate Cancer | March 16, 2011 | Phase 2 |
NCT01017939 | Janssen Research & Development, LLC | Prostate Neoplasms | January 2010 | Phase 1 |
NCT00910754 | Janssen Research & Development, LLC | Prostate Neoplasms | May 2009 | Phase 1 |
NCT04296578 | Stanford University | Prostate Cancer|Castrate Resistant Prostate Cancer | October 2020 | Phase 1 |
NCT00473512 | Cougar Biotechnology, Inc. | Prostatic Neoplasms | November 2005 | Phase 1|Phase 2 |
NCT03016741 | Northwestern University | Castration-Resistant Prostatic Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer|Hormone-Refractory Prostate Cancer | March 31, 2017 | Phase 4 |
NCT05422911 | James J. Peters Veterans Affairs Medical Center | Metastatic Cancer|Neoplasm, Prostate | June 30, 2022 | Phase 2 |
NCT04862091 | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-resistant Prostate Cancer (mCRPC) | April 23, 2021 | Phase 2 |
NCT05593497 | VA Office of Research and Development | High-Risk Prostate Cancer | June 1, 2023 | Phase 2 |
NCT03732820 | AstraZeneca|Merck Sharp & Dohme LLC | Metastatic Castration-resistant Prostate Cancer | October 31, 2018 | Phase 3 |
NCT00600535 | Cougar Biotechnology, Inc. | Prostate Neoplasms | July 2007 | Phase 1 |
NCT01792687 | Aragon Pharmaceuticals, Inc. | Prostate Cancer | February 2013 | Phase 1 |
NCT02090114 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Prostate Cancer | August 25, 2014 | Phase 2 |
NCT03458247 | Assistance Publique - Hôpitaux de Paris|Janssen, LP | Prostate Cancer | June 22, 2018 | Phase 2 |
NCT05968599 | Pfizer|Astellas Pharma Inc | Prostatic Neoplasms, Castration-Resistant | August 1, 2023 | |
NCT02364531 | Janssen Inc. | Prostatic Neoplasms | September 30, 2014 | |
NCT00474383 | Cougar Biotechnology, Inc. | Prostate Neoplasms | November 2006 | Phase 2 |
NCT00485303 | Cougar Biotechnology, Inc. | Prostatic Neoplasms|Prostate Cancer | June 2007 | Phase 2 |
NCT01858441 | Centre Antoine Lacassagne | Pharmacogenetic Study | April 2013 | Not Applicable |
NCT03903835 | Karolinska Institutet|The Swedish Research Council|Kom Op Tegen Kanker|Janssen Pharmaceutica N.V., Belgium | Metastatic Castration-resistant Prostate Cancer|Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | February 1, 2019 | Phase 3 |
NCT02125357 | British Columbia Cancer Agency | Metastatic Castration-Resistant Prostate Cancer | September 2014 | Phase 2 |
NCT02001571 | Cougar Biotechnology, Inc. | Prostate Cancer | August 2009 | Phase 1 |
NCT03009981 | Alliance Foundation Trials, LLC.|Janssen Research & Development, LLC | Prostate Cancer | March 6, 2017 | Phase 3 |
NCT05367440 | AstraZeneca|Bayer | Metastatic Prostate Cancer | June 2, 2022 | Phase 1|Phase 2 |
NCT01786265 | M.D. Anderson Cancer Center | Prostate Adenocarcinoma|Recurrent Prostate Carcinoma | February 5, 2013 | Phase 2 |
NCT03748641 | Janssen Research & Development, LLC | Castration-Resistant Prostatic Cancer | January 25, 2019 | Phase 3 |
NCT03833921 | Martha Mims|Baylor College of Medicine | Prostate Cancer Metastatic|Prostate Cancer | May 23, 2019 | Phase 2 |
NCT03999515 | University of Washington|Janssen Research & Development, LLC | Castration-Resistant Prostate Carcinoma|Double-Negative Prostate Carcinoma|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | April 27, 2020 | Phase 2 |
NCT01685983 | Janssen Research & Development, LLC | Prostate Cancer | August 30, 2011 | Phase 2 |
NCT02913196 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC | Prostate Cancer Metastatic | December 30, 2016 | Phase 1 |
NCT04139772 | National Cancer Institute, Naples | Metastatic Castration-resistent Prostate Cancer | September 1, 2019 | Phase 3 |
NCT01946165 | M.D. Anderson Cancer Center|Janssen Services, LLC|Medivation, Inc. | Prostate Cancer | October 31, 2013 | Phase 2 |
NCT00638690 | Cougar Biotechnology, Inc. | Prostatic Neoplasms | May 2008 | Phase 3 |
NCT05156450 | West China Hospital | Prostatic Neoplasms, Castration-Resistant|Drug Therapy, Combination | January 1, 2022 | Phase 2 |
NCT04556617 | Opna-IO LLC | Metastatic Castration-resistant Prostate Cancer | September 21, 2020 | Phase 1|Phase 2 |
NCT01503229 | University of Washington|National Cancer Institute (NCI) | Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Adenocarcinoma | December 2012 | Phase 2 |
NCT01692483 | Janssen Pharmaceutica | Prostate Neoplasms | July 2013 | |
NCT03902951 | Jonsson Comprehensive Cancer Center|Janssen Inc. | Metastatic Prostate Adenocarcinoma|Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation|Recurrent Prostate Carcinoma|Stage IVB Prostate Cancer AJCC v8 | March 17, 2021 | Phase 2 |
NCT02218606 | Memorial Sloan Kettering Cancer Center|Sanofi|Thomas Jefferson University|Weill Medical College of Cornell University | Prostate Cancer | August 2014 | Phase 2 |
NCT04497844 | Janssen Research & Development, LLC | Metastatic Castrate Sensitive Prostate Cancer | September 23, 2020 | Phase 3 |
NCT03012321 | Northwestern University|AstraZeneca|National Cancer Institute (NCI) | Prostate Cancer Metastatic Castration-Resistant|Abnormal DNA Repair|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer | January 2017 | Phase 2 |
NCT01685125 | University of Southern California|National Cancer Institute (NCI) | Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer | September 2012 | Phase 2 |
NCT01695135 | Janssen Research & Development, LLC | Prostate Neoplasms | August 9, 2012 | Phase 3 |
NCT01543776 | University of Chicago|National Cancer Institute (NCI) | Castration-resistant Prostate Cancer|Stage IV Prostate Cancer | January 2012 | Phase 2 |
NCT04691804 | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | March 18, 2021 | Phase 3 |
NCT02807805 | Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis | Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer | October 2016 | Phase 2 |
NCT02257736 | Aragon Pharmaceuticals, Inc. | Prostatic Neoplasms | November 26, 2014 | Phase 3 |
NCT01940276 | Duke University | Prostate Cancer | October 2013 | Phase 2 |
NCT01685268 | Astex Pharmaceuticals, Inc. | Prostate Cancer | September 2012 | Phase 1|Phase 2 |
NCT01842321 | UNICANCER | Breast Cancer | July 2013 | Phase 2 |
NCT01735396 | Icahn School of Medicine at Mount Sinai | Prostate Cancer | December 2012 | Phase 2 |
NCT04356430 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Prostate Cancer | April 1, 2019 | Phase 2 |
NCT00755885 | Cancer Research UK | Breast Cancer | October 2008 | Phase 1|Phase 2 |
NCT02849990 | University of Washington|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) | Stage III Prostate Adenocarcinoma AJCC v7|Stage III Prostate Cancer AJCC v7|Stage IV Prostate Adenocarcinoma AJCC v7|Stage IV Prostate Cancer AJCC v7 | March 9, 2017 | Phase 2 |
NCT03548246 | University of Texas Southwestern Medical Center|National Institutes of Health Clinical Center (CC)|University of Michigan|Children´s Hospital Los Angeles|Feinstein Institute for Medical Research | Congenital Adrenal Hyperplasia | January 2023 | Phase 2 |
NCT02353715 | Duke University | Prostate Cancer | July 7, 2015 | |
NCT02740985 | AstraZeneca | Advanced Solid Malignancies|Non-Small Cell Lung Cancer (NSCLC)|Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)|Colorectal Carcinoma (CRC) | June 17, 2016 | Phase 1 |
NCT01314118 | Janssen Biotech, Inc. | Prostate Cancer|Prostatic Neoplasm | May 4, 2011 | Phase 2 |
NCT00544440 | Janssen Research & Development, LLC | Prostate Neoplasms | October 2007 | Phase 2 |
NCT02025010 | Dana-Farber Cancer Institute|Janssen Research & Development, LLC | Castration-resistant Prostate Cancer | January 27, 2014 | Phase 2 |
NCT04071262 | Eli Lilly and Company | Advanced Cancer | December 20, 2019 | Phase 1 |
NCT01217697 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Prostate Neoplasms|Genital Neoplasms, Male|Urogenital Neoplasms|Genital Diseases, Male | | |
NCT01681433 | Costantine Albany|Hoosier Cancer Research Network|Achieve Life Sciences | Prostate Cancer|Metastatic Castrate-Resistant Prostate Cancer|PSA | December 2012 | Phase 2 |
NCT01381874 | Janssen Research & Development, LLC | Metastatic ER&addition; Her2- Breast Cancer|Postmenopausal | August 24, 2011 | Phase 2 |
NCT02867852 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Salivary Glands Tumors | March 2015 | Phase 2 |
NCT02077634 | Universität des Saarlandes | Prostate Cancer | May 2014 | Phase 2 |
NCT04869488 | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration Resistant Prostate Cancer | July 26, 2021 | Phase 2 |
NCT04194554 | University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC | Prostate Cancer | November 6, 2020 | Phase 1|Phase 2 |
NCT01088529 | Cougar Biotechnology, Inc. | Prostate Cancer | December 2009 | Phase 2 |
NCT04812366 | University of British Columbia|Janssen Inc.|University Health Network, Toronto | Prostate Cancer | September 21, 2021 | Phase 2 |
NCT02987543 | AstraZeneca|Merck Sharp & Dohme LLC|Foundation Medicine, Inc.|Myriad Genetics, Inc. | Metastatic Castration-resistant Prostate Cancer | February 6, 2017 | Phase 3 |
NCT01834209 | Janssen Research & Development, LLC | Prostate Neoplasms | | |
NCT04295161 | Zentiva, k.s. | Pharmacokinetics | June 25, 2019 | Phase 1 |
NCT01637402 | Terence Friedlander, MD|Janssen Biotech, Inc.|University of California, San Francisco | Castration Resistant Prostate Cancer | March 13, 2013 | Phase 2 |
NCT03436654 | Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute | Prostate Cancer | June 21, 2018 | Phase 2 |
NCT01362764 | Cougar Biotechnology, Inc. | Healthy Volunteers | May 2011 | Phase 1 |
NCT01487863 | Dendreon | Prostate Cancer Metastatic|Hormone Refractory Prostate Cancer|Castration-resistant Prostate Cancer | December 2011 | Phase 2 |
NCT01517802 | Janssen Research & Development, LLC | Metastatic Castration-resistant Prostate Cancer|Metastatic Breast Cancer | March 28, 2012 | Phase 3 |
NCT03777982 | Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC | Prostate Cancer | April 20, 2020 | Phase 3 |
NCT02962284 | Sun Pharmaceutical Industries Limited | Metastatic Prostate Cancer | November 2016 | Phase 2 |
NCT05212857 | Fudan University | Prostate Cancer | April 2022 | Phase 2 |
NCT04056754 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration Resistant Prostate Cancer | July 16, 2014 | Phase 3 |
NCT01994590 | M.D. Anderson Cancer Center|Novartis | Prostate Cancer | May 19, 2014 | Phase 2 |
NCT03821792 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Carcinoma Metastatic in the Bone|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | July 22, 2019 | Phase 2 |
NCT05457257 | AstraZeneca|Merck Sharp & Dohme LLC|Foundation Medicine, Inc.|Myriad Genetics, Inc. | Metastatic Castration-resistant Prostate Cancer | July 29, 2022 | Phase 4 |
NCT01650194 | Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc | Metastatic Castration-Resistant Prostate Cancer | July 9, 2012 | Phase 2 |
NCT01845792 | University of Colorado, Denver|Janssen Services, LLC | Prostate Cancer | July 2013 | Phase 2 |
NCT01678573 | Janssen Research & Development, LLC | Healthy | July 2012 | Phase 1 |
NCT04879589 | Syneos Health|Antares Pharma Inc. | Metastatic Castration-resistant Prostate Cancer | September 1, 2022 | Phase 1 |
NCT02903368 | Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC | Prostate Cancer | October 19, 2016 | Phase 2 |
NCT05223582 | Fudan University | High-risk Prostate Cancer|Neoadjuvant Therapy | May 1, 2021 | Phase 2 |
NCT02123758 | Aragon Pharmaceuticals, Inc. | Prostatic Neoplasms|Metastatic Castration-Resistant Prostate Cancer | July 9, 2014 | Phase 1 |
NCT03356444 | West China Hospital | Prostate Cancer|Castration-resistant Prostate Cancer|Drug | November 2017 | Phase 2 |
NCT02608359 | Johnson & Johnson Private Limited | Prostate Cancer | May 31, 2016 | |
NCT02924766 | Janssen Research & Development, LLC | Prostatic Neoplasms | October 3, 2016 | Phase 1 |
NCT02703623 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7 | May 18, 2016 | Phase 2 |
NCT02426333 | Radboud University Medical Center|Janssen-Cilag Ltd. | Metastatic Castration Resistant Prostate Cancer | January 2016 | |
NCT01664728 | Janssen Research & Development, LLC | Prostate Neoplasms | April 2007 | Phase 1 |
NCT03419234 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|Stage IV Prostate Adenocarcinoma AJCC v7 | April 26, 2018 | Phase 2 |
NCT01873001 | Janssen Research & Development, LLC | Healthy Volunteers | May 2013 | Phase 1 |
NCT02230046 | Janssen Research & Development, LLC | Healthy | October 2014 | Phase 1 |
NCT01495910 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 21-hydroxylase Deficiency | December 2011 | Phase 1 |
NCT03279250 | M.D. Anderson Cancer Center | Prostate Adenocarcinoma|Stage IIB Prostate Cancer AJCC v8|Stage IIC Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8 | October 13, 2017 | Phase 2 |
NCT01023061 | University of Washington|National Cancer Institute (NCI) | Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer | March 2010 | Phase 2 |
NCT03827473 | University of Utah | Castration-Sensitive Prostate Carcinoma|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer|Stage IVA Prostate Cancer|Stage IVB Prostate Cancer | February 8, 2019 | Phase 2 |
NCT02887976 | GU Research Network, LLC|Churchill Pharmaceutical LLC | Prostate Cancer | September 2016 | Phase 3 |
NCT03360721 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Castration-Resistant Prostate Carcinoma|Prostate Adenocarcinoma Without Neuroendocrine Differentiation|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | March 6, 2018 | Phase 2 |
NCT03145285 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Niguarda Hospital|San Camillo Hospital, Rome|San Luigi Gonzaga Hospital | Cushing Syndrome|Adrenocortical Carcinoma | April 18, 2017 | Phase 2 |
NCT04863105 | The Affiliated Hospital of Qingdao University | Healthy Volunteers | November 24, 2017 | Phase 1 |
NCT05405439 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | August 25, 2022 | Phase 1|Phase 2 |
NCT05406999 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Neoadjuvant Therapy|High Risk Prostate Cancer|Locally Advanced Prostate Cancer|Intense Endocrine Therapy | February 1, 2020 | Phase 2 |
NCT03449719 | Lorenzo Livi|Azienda Ospedaliero-Universitaria Careggi | Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone | May 1, 2018 | Not Applicable |
NCT01814865 | British Columbia Cancer Agency|Janssen Research & Development, LLC | Post-menopausal ER&addition; Stage I-IIIA Primary Operable Breast Cancer | May 2013 | Phase 2 |
NCT05167175 | Hongqian Guo|AstraZeneca|Nanjing Chia-tai Tianqing Pharmaceutical|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Prostate Cancer|Prostate Carcinoma|Metastatic Prostate Cancer | March 1, 2022 | Phase 2 |
NCT04577833 | Janssen Research & Development, LLC | Prostatic Neoplasms | November 13, 2020 | Phase 1 |
NCT01957436 | UNICANCER|Janssen-Cilag Ltd.|European Organisation for Research and Treatment of Cancer - EORTC|Ipsen|Sanofi | Metastatic Prostate Cancer | November 13, 2013 | Phase 3 |
NCT01655147 | Janssen Research & Development, LLC | Healthy | January 2012 | Phase 1 |
NCT04477512 | Washington University School of Medicine|Bristol-Myers Squibb|Exelixis | Metastatic Hormone Refractory Prostate Cancer | February 19, 2021 | Phase 1 |
NCT02861573 | Merck Sharp & Dohme LLC | Metastatic Castration-Resistant Prostate Cancer | November 17, 2016 | Phase 1|Phase 2 |
NCT02960022 | Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc | Prostate Cancer | December 22, 2016 | Phase 2 |
NCT02737332 | Sun Pharmaceutical Industries Limited | Prostate Cancer | March 21, 2016 | Phase 2 |
NCT01309672 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Prostate Cancer | August 9, 2011 | Phase 2 |
NCT04734730 | City of Hope Medical Center|National Cancer Institute (NCI) | Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | May 4, 2021 | Phase 2 |
NCT02949284 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) | Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma | June 20, 2017 | Phase 2 |
NCT05520138 | Pfizer | Prostatic Neoplasms, Castration-Resistant | August 29, 2022 | |
NCT03565835 | Montefiore Medical Center | Prostatic Neoplasms | June 13, 2018 | Phase 2 |
NCT03007732 | Lawrence Fong|Prostate Cancer Foundation|Merck Sharp & Dohme LLC|Dynavax Technologies Corporation|University of California, San Francisco | Prostatic Neoplasms | May 17, 2017 | Phase 2 |
NCT04267887 | OHSU Knight Cancer Institute|Janssen Scientific Affairs, LLC|Oregon Health and Science University | Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IVB Prostate Cancer AJCC v8 | May 11, 2020 | Phase 2 |
NCT01798628 | Cougar Biotechnology, Inc. | Healthy Volunteers | September 2009 | Phase 1 |
NCT02034552 | Bayer | Prostatic Neoplasms | March 7, 2014 | Phase 2 |
NCT01715285 | Janssen Research & Development, LLC | Prostate Neoplasms | February 12, 2013 | Phase 3 |
NCT05171816 | AstraZeneca|Merck Sharp & Dohme LLC | Metastatic Castration-resistant Prostate Cancer | June 24, 2021 | Phase 3 |
NCT02268175 | Dana-Farber Cancer Institute|Medivation, Inc. | Prostate Adenocarcinoma|Prostate Cancer|High Risk Prostate Cancer | October 2014 | Phase 2 |
NCT05588609 | Merus N.V. | NSCLC Harboring NRG1 Fusion|Metastatic Castration-resistant Prostate Cancer | November 17, 2022 | Phase 2 |
NCT00473746 | Janssen Research & Development, LLC | Prostate Neoplasms | June 2006 | Phase 1|Phase 2 |
NCT05401214 | Janssen Research & Development, LLC | Metastatic Castration-resistant Prostate Cancer | | |
NCT01717898 | Charles Ryan|Novartis Pharmaceuticals|University of California, San Francisco | Castrate-resistant Prostate Cancer | January 31, 2013 | Phase 1|Phase 2 |
NCT02903160 | Icahn School of Medicine at Mount Sinai|Sanofi|Bayer | Prostate Cancer | January 13, 2017 | Phase 2 |
NCT03834519 | Merck Sharp & Dohme LLC | Prostatic Neoplasms | May 2, 2019 | Phase 3 |
NCT02379390 | Sanofi | Prostate Cancer Metastatic | June 17, 2015 | Phase 2 |
NCT03649841 | University of Washington|National Cancer Institute (NCI) | Castration-Sensitive Prostate Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma|Prostate Small Cell Neuroendocrine Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 | June 29, 2020 | Phase 2 |
NCT01393730 | Mary-Ellen Taplin, MD|Dana-Farber Cancer Institute | Prostate Cancer | September 2011 | Phase 2 |
NCT04175431 | University of Washington|Blue Earth Diagnostics | Prostate Adenocarcinoma | September 30, 2020 | Phase 2 |
NCT01576172 | National Cancer Institute (NCI) | Castration-Resistant Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer AJCC v7 | March 30, 2012 | Phase 2 |
NCT04446117 | Exelixis|Roche-Genentech|Takeda | Metastatic Prostate Cancer|Prostate Adenocarcinoma | June 30, 2020 | Phase 3 |
NCT05295927 | Janssen Research & Development, LLC | Prostatic Neoplasms | March 23, 2022 | Phase 1 |
NCT01715259 | Cougar Biotechnology, Inc. | Renal Insufficiency | August 2009 | Phase 1 |
NCT02656615 | Aurelius Omlin|Cantonal Hospital of St. Gallen|University Hospital, Basel, Switzerland | Prostate Cancer | January 2016 | Phase 2 |
NCT01199146 | University of California, San Francisco|Johnson & Johnson|Cougar Biotechnology, Inc. | Prostate Cancer | September 10, 2010 | Phase 2 |
NCT00887198 | Janssen Research & Development, LLC | Prostate Cancer | April 28, 2009 | Phase 3 |
NCT02975934 | zr Pharma & GmbH|Foundation Medicine | Metastatic Castration Resistant Prostate Cancer | June 13, 2017 | Phase 3 |
NCT02159690 | Kenneth Pienta, MD|Prostate Cancer Foundation Norway|Johns Hopkins University | Prostate Cancer|Localized Prostate Cancer | September 2014 | Phase 2 |
NCT04291664 | DisperSol Technologies, LLC|Translational Drug Development | Prostate Cancer | January 31, 2020 | Phase 1 |
NCT02097303 | Carolina Research Professionals, LLC|Bayer | Prostate Cancer | March 2014 | Phase 2 |
NCT03568656 | CellCentric Ltd. | Metastatic Castration-Resistant Prostate Cancer|Metastatic Breast Cancer|Non-small Cell Lung Cancer|Advanced Solid Tumors | July 23, 2018 | Phase 1|Phase 2 |
NCT02574910 | University of Texas Southwestern Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Michigan|Children´s Hospital Los Angeles | Congenital Adrenal Hyperplasia | August 1, 2017 | Phase 1 |
NCT02405858 | Janssen Pharmaceutical K.K. | Metastatic Castration-Resistant Prostate Cancer | April 10, 2015 | Phase 4 |
NCT03706365 | Eli Lilly and Company | Prostate Cancer | November 26, 2018 | Phase 2|Phase 3 |
NCT05137262 | M.D. Anderson Cancer Center|AstraZeneca | Urothelial Carcinoma|Bladder Cancer | October 13, 2021 | Phase 2 |
NCT02485691 | Sanofi | Prostate Cancer Metastatic | November 9, 2015 | Phase 4 |
NCT01511536 | Sanofi | Prostate Cancer | March 2012 | Phase 1|Phase 2 |
NCT01884285 | AstraZeneca | Advanced Castrate-resistant Prostate Cancer CRPC|Squamous Non-Small Cell Lung Cancer sqNSCLC|Triple Negative Breast Cancer TNBC | July 9, 2013 | Phase 1 |